These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 29725339)

  • 1. Efficient Capsid Antigen Presentation From Adeno-Associated Virus Empty Virions
    Pei X; Earley LF; He Y; Chen X; Hall NE; Samulski RJ; Li C
    Front Immunol; 2018; 9():844. PubMed ID: 29725339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adeno-associated virus capsid antigen presentation is dependent on endosomal escape.
    Li C; He Y; Nicolson S; Hirsch M; Weinberg MS; Zhang P; Kafri T; Samulski RJ
    J Clin Invest; 2013 Mar; 123(3):1390-401. PubMed ID: 23454772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical.
    He Y; Weinberg MS; Hirsch M; Johnson MC; Tisch R; Samulski RJ; Li C
    Hum Gene Ther; 2013 May; 24(5):545-53. PubMed ID: 23534873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of CpG Sequences on Capsid-Specific CD8
    Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ
    Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.
    Finn JD; Hui D; Downey HD; Dunn D; Pien GC; Mingozzi F; Zhou S; High KA
    Mol Ther; 2010 Jan; 18(1):135-42. PubMed ID: 19904235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
    Li C; Hirsch M; DiPrimio N; Asokan A; Goudy K; Tisch R; Samulski RJ
    J Virol; 2009 Jul; 83(13):6817-24. PubMed ID: 19369348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors.
    Yan Z; Zak R; Luxton GW; Ritchie TC; Bantel-Schaal U; Engelhardt JF
    J Virol; 2002 Mar; 76(5):2043-53. PubMed ID: 11836382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of Assembly-Activating Protein for Adeno-associated Virus Vector Production and Capsid Protein Stability in Mammalian and Insect Cells.
    Grosse S; Penaud-Budloo M; Herrmann AK; Börner K; Fakhiri J; Laketa V; Krämer C; Wiedtke E; Gunkel M; Ménard L; Ayuso E; Grimm D
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.
    Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW
    Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses to AAV in clinical trials.
    Mingozzi F; High KA
    Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Genome Packaging Efficiency of Adeno-associated Virus Vectors Using Rep Hybrids.
    Mietzsch M; Eddington C; Jose A; Hsi J; Chipman P; Henley T; Choudhry M; McKenna R; Agbandje-McKenna M
    J Virol; 2021 Sep; 95(19):e0077321. PubMed ID: 34287038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets.
    Wang L; Figueredo J; Calcedo R; Lin J; Wilson JM
    Hum Gene Ther; 2007 Mar; 18(3):185-94. PubMed ID: 17324107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity.
    Rossi A; Dupaty L; Aillot L; Zhang L; Gallien C; Hallek M; Odenthal M; Adriouch S; Salvetti A; Büning H
    Sci Rep; 2019 Mar; 9(1):3631. PubMed ID: 30842485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
    Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
    Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome.
    Wu TL; Li H; Faust SM; Chi E; Zhou S; Wright F; High KA; Ertl HC
    Mol Ther; 2014 Jan; 22(1):42-51. PubMed ID: 24077034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production.
    Halbert CL; Metzger MJ; Lam SL; Miller AD
    Gene Ther; 2011 Apr; 18(4):411-7. PubMed ID: 21160534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.
    Pien GC; Basner-Tschakarjan E; Hui DJ; Mentlik AN; Finn JD; Hasbrouck NC; Zhou S; Murphy SL; Maus MV; Mingozzi F; Orange JS; High KA
    J Clin Invest; 2009 Jun; 119(6):1688-95. PubMed ID: 19436115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes.
    Hui DJ; Basner-Tschakarjan E; Chen Y; Davidson RJ; Buchlis G; Yazicioglu M; Pien GC; Finn JD; Haurigot V; Tai A; Scott DW; Cousens LP; Zhou S; De Groot AS; Mingozzi F
    Mol Ther; 2013 Sep; 21(9):1727-37. PubMed ID: 23857231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular Inflammatory Response to Intravitreal Injection of Adeno-Associated Virus Vector: Relative Contribution of Genome and Capsid.
    Timmers AM; Newmark JA; Turunen HT; Farivar T; Liu J; Song C; Ye GJ; Pennock S; Gaskin C; Knop DR; Shearman MS
    Hum Gene Ther; 2020 Jan; 31(1-2):80-89. PubMed ID: 31544533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.